SOST and plasma cell myeloma: Clinical studies reported that serum levels of sclerostin positively correlate with the progression of multiple myeloma as well as those of macrophage inflammatory protein-1α which is secreted from multiple myeloma plasma cells and involved in the development of myeloma-related bone diseases [90,91,92].